Divergent Planning LLC Purchases New Stake in Johnson & Johnson $JNJ

Key Points

• Divergent Planning LLC has acquired a new stake in Johnson & Johnson, purchasing 3,585 shares valued at approximately $548,000 during the 2nd quarter.
• Johnson & Johnson reported $2.77 earnings per share for the last quarter, exceeding analysts' estimates, with revenue of $23.74 billion, a 5.8% increase from the previous year.
• The company recently declared a quarterly dividend of $1.30 per share, resulting in an annualized dividend yield of 2.9% and a payout ratio of 55.61%.

Divergent Planning LLC bought a new stake in Johnson & Johnson (NYSE:JNJ - Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 3,585 shares of the company's stock, valued at approximately $548,000.

Other hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC boosted its position in shares of Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after buying an additional 6,332 shares during the period. Hudson Value Partners LLC lifted its position in Johnson & Johnson by 2.5% during the 4th quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after acquiring an additional 1,022 shares in the last quarter. Two Sigma Investments LP purchased a new position in Johnson & Johnson in the 4th quarter worth approximately $9,222,000. Two Sigma Advisers LP raised its stake in shares of Johnson & Johnson by 48.1% during the fourth quarter. Two Sigma Advisers LP now owns 189,343 shares of the company's stock valued at $27,383,000 after purchasing an additional 61,493 shares during the period. Finally, Twinbeech Capital LP boosted its stake in shares of Johnson & Johnson by 235.7% in the fourth quarter. Twinbeech Capital LP now owns 108,857 shares of the company's stock valued at $15,743,000 after purchasing an additional 76,428 shares during the period. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

Johnson & Johnson stock traded up $1.81 during midday trading on Friday, reaching $175.97. 25,617,065 shares of the stock traded hands, compared to its average volume of 6,995,150. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $181.16. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The firm has a market cap of $423.80 billion, a price-to-earnings ratio of 18.82, a PEG ratio of 2.22 and a beta of 0.40. The firm has a fifty day moving average price of $172.80 and a two-hundred day moving average price of $161.69.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same period in the previous year, the firm posted $2.82 earnings per share. The business's revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is currently 55.61%.

Analyst Upgrades and Downgrades

A number of brokerages have commented on JNJ. Wall Street Zen upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Saturday, September 13th. Morgan Stanley increased their price objective on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday, July 17th. UBS Group increased their price target on shares of Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a research report on Thursday, July 17th. Bank of America upped their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a research note on Thursday, July 17th. Finally, Guggenheim reiterated a "neutral" rating and set a $167.00 target price (up previously from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and ten have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $177.87.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.